Deep vein thrombosis screening: Difference between revisions
Jump to navigation
Jump to search
Kashish Goel (talk | contribs) No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{{DVT editors}} | |||
{{Deep vein thrombosis}} | {{Deep vein thrombosis}} | ||
Revision as of 20:17, 13 June 2012
Editor(s)-In-Chief: The APEX Trial Investigators, C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2] Ujjwal Rastogi, MBBS [3]; Kashish Goel, M.D.; Assistant Editor(s)-In-Chief: Justine Cadet
|
Deep Vein Thrombosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Special Scenario |
|
Trials |
|
Case Studies |
|
Deep vein thrombosis screening On the Web |
|
Risk calculators and risk factors for Deep vein thrombosis screening |
Value of screening
In-spite of identifying patients at increased risk of VTE, there is no clear clinical value for screening the general population because:
- The strongest risk factor for VTE recurrence is a prior VTE event itself.
- VTE patients with unknown cause have a high rate of recurrence, after discontinuation of warfarin, irrespective of the presence of inherited thrombophilia.
- Anticoagulant prophylaxis is rarely recommended in asymptomatic affected family members, outside of high risk situations.
Who should be screened?
Screening for inherited thrombophilia in patients who have DVT is discussed here.